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Keywords :  26  Diabetic retinopathy  27  PACAP  28  TUNEL  29  Caspases  30 Anti-apoptotic factors 31 3 2 a b s t r a c t Metabolic changes induced by diabetes lead to a multifactorial progressive disease of the retina with an 34 extremely complex pathogenesis. One of the mechanisms of retinal cell death in diabetes is via apoptosis. 35 Our previous results show that pituitary adenylate cyclase activating polypeptide (PACAP) attenuates the 36 morphological and neurochemical changes in a rat model of diabetic retinopathy. The aim of this study 37 was to investigate the mechanisms of this protective effect. 38 Retinas of streptozotocin-induced diabetic rats were analyzed using apoptosis detection combined 39 with immunolabeling. Western blot was used to measure levels of pro-and anti-apoptotic pathways. 40 Intraocular PACAP injection markedly attenuated diabetic retinal injury: increased levels of the anti-41 apoptotic p-Akt, p-ERK1, p-ERK2, PKC, Bcl-2, while decreased levels of the pro-apoptotic p-p38MAPK 42 and activated caspases (8, 3, 12) were detected. The number of apoptotic cells increased in all nuclear lay-43 ers of diabetic retinas, but significantly decreased after PACAP treatment. Our results clearly demonstrate 44 that the protective effects of PACAP are mediated, at least partly, by attenuating apoptosis, including also 45 that of the dopaminergic amacrine cells. Inhibition of apoptosis is one of the PACAP-induced pathways 46 with therapeutic potential in early experimental diabetic retinopathy. Abbreviations: ER, endoplasmatic reticulum; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GCL, ganglion cell layer; GSK3b, glycogen synthase kinase 3 beta; ERKs, extracellular signal-regulated kinases; INL, inner nuclear layer; IPL, inner plexiform layer; MAPKs, mitogen activated protein kinases; ONL, outer nuclear layer; OPL, outer plexiform layer; PACAP, pituitary adenylate cyclase activating polypeptide; PAC1-R, PACAP type 1 receptor; PKA, protein kinase A; PKC, protein kinase C; TH, tyrosine hydroxylase; TUNEL, terminal transferase dUTP nick end labeling; VIP, vasoactive intestinal peptide. glial, and ganglion cells (Fig. 1C) . Fig. 2A,B,C) . The activated (cleaved) 276 form of both caspase 3 and caspase 12 could be detected only in 277 the diabetic retinas (Figs. 2B,C) . In addition, diabetes increased 278 the total protein level of the p38MAPK and the phosphorylation 279 of the pro-apoptotic p38MAPK, which was significantly attenuated 280 by PACAP treatment (Fig. 3) .
281
Total ERK1 levels increased in diabetes compared to control, It has been shown that p38MAPK inhibitor SB202190 decreased Retinal caspase 8, caspase 3, and caspase 12 levels in diabetic eyes were significantly decreased in PACAP-treated diabetic eyes. Diabetes significantly increased both the non-activated (caspase 8-55 kDa, caspase 3-32 kDa, and caspase 12-55 kDa) and the cleaved (caspase 8-31 kDa and 26 kDa, caspase 3-12 kDa, and caspase 12-36 kDa) form of caspase 8, caspase 3, and caspase 12, whereas treatment with PACAP reduced both the active and the cleaved forms of the examined caspases. Data are presented as mean ± SEM. ⁄⁄ p < 0.001 compared to control; ## p < 0.001 compared to diabetic retinas (oneway ANOVA with Tukey-B posthoc analysis). Fig. 3 . Analysis of p38MAPK and p-p38MAPK in control, control + PACAP, diabetic, and PACAP-treated diabetic retinas. GAPDH served as normalization control. Results are presented in blots and relative quantities (arbitrary unit).After 3 weeks of diabetes, expression of the pro-apoptotic factor p38MAPK and p-p38MAPK was significantly higher in the retinas from control animals, while significantly decreased in the PACAP-treated diabetic retinas. Data are presented as mean ± SEM. ⁄⁄ p < 0.001 compared to control; ## p < 0.001 compared to diabetic retinas (one-way ANOVA with Tukey-B posthoc analysis). 
